<DOC>
	<DOCNO>NCT02587884</DOCNO>
	<brief_summary>The aim study explore effect Transarterial Chemoembolization ( TACE ) prognosis patient microvascular invasion presence ( MVI ) overexpression Aspartate-β-hydroxylase ( ASPH ) .</brief_summary>
	<brief_title>Anti-recurrence Treatment Postresection HCC Patients With MVI Presence Over-expression ASPH</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1 . Via clinical diagnosis confirm primary liver cancer 2 . Pathological evidence HCC 3 . Confirm presence MVI overexpression ASPH opreation 4 . Within Milan criteria 5 . Estimate tumor gain treatment cure operation 6 . No evidence extrahepatic metestasis 7. liver function ：ChildPugh A/B 1 . Reject attend 2 . Impossible come hospital physical examination regularly 3 . Patients apparent cardiac , pulmonary , cerebral renal dysfunction 4 . Female pregnancy lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Recurrence</keyword>
	<keyword>Microvascular Invasion</keyword>
	<keyword>Aspartate beta-hydroxylase</keyword>
</DOC>